The Use of First Line Highly Active Anti-Retroviral Therapy (HAART) is not Associated with QTc Prolongation in HIV Patients.
No Thumbnail Available
Date
2017
Journal Title
Journal ISSN
Volume Title
Publisher
College of Health Sciences, Jimma University Ethiopia
Abstract
BACKGROUND: HAART has improved survival of HIV patients.
Its contribution to the development of new cardiovascular
abnormalities has generated much interest. This study aimed at
determining the prevalence of QTc prolongation among HIV
patients and determining the influence if any of the use of HAART
on the QTc and on the risk of having QTc prolongation.
Sci.2017;27(6):613.
MATERIALS AND METHODS: One hundred and fifty HIV
positive subjects comprising 76 HIV positive subjects on HAART
(Group A), 74 who were HAART- naïve (Group B), and 150 age
and sex-matched healthy controls (Group C) were studied. All
subjects had electrocardiography, and QTc duration was
calculated.
RESULTS: Mean QTc was significantly different among the three
groups (P <0.001), highest in Group B > Group A > Group C.
Frequency of QTc prolongation was highest in Group B (32%)>,
Group A (17.3%)> Group C (4.7%) (P<0.001). Mean QTc was
significantly longer among patients with CD4 count <200
cells/mm than among those with >200 cells/mm
0.445 + 0.03secs vs 0.421 + 0.03secs (P<0.001). QTc prolongation was commoner
among individuals with CD4 count <200 cells/mm 50% vs 20.5%
(P<0.001). On binary logistic regression, none of the HAART
medications used by our patients was predictive of the occurrence
of QTc prolongation.
CONCLUSION: The QTc is longer, and QTc prolongation occurs
more frequently in HAART-naïve HIV patients than patients on
HAART and healthy controls. None of the HAART medications
used by our patients was predictive of the development of QTc
prolongation.
Description
Keywords
QTc prolongation, HIV/AIDS, Highly Active AntiRetroviral Therapy (HAART)
Citation
Ethiopian Journal of Health Sciences 27(6):613-620